 |
36 Diseases |  |
5 Trials |
|
5 Trials |  |
637 News |  |
| «12345678910» |
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: RESTORE: A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Na (clinicaltrials.gov) - Apr 13, 2014
P3, N=107, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed
- ||||| Olysio (simeprevir) / J&J, Medivir
New P4 trial, HEOR: A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir (clinicaltrials.gov) - Apr 2, 2014
P4, N=300, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
- TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Enrollment open, Combination therapy: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants (clinicaltrials.gov) - Mar 27, 2014
P1, N=48, Recruiting, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Olysio (simeprevir) / J&J, Medivir
Enrollment change, Combination therapy: A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study (clinicaltrials.gov) - Mar 5, 2014
P3, N=142, Active, not recruiting, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting N=270 --> 142
- | Olysio (simeprevir) / J&J, Medivir
Enrollment closed, Combination therapy: A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study (clinicaltrials.gov) - Mar 5, 2014
P3, N=142, Active, not recruiting, Sponsor: Janssen R&D Ireland
N=270 --> 142 Recruiting --> Active, not recruiting
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients (clinicaltrials.gov) - Feb 24, 2014
P2a, N=168, Completed, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants (clinicaltrials.gov) - Feb 23, 2014
P1, N=32, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- GSK 2336805 / J&J, Olysio (simeprevir) / J&J, Medivir
Enrollment closed: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants. (clinicaltrials.gov) - Feb 19, 2014
P1, N=48, Active, not recruiting, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
New P1 trial, Combination therapy: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants (clinicaltrials.gov) - Feb 13, 2014
P1, N=48, Recruiting, Sponsor: Janssen R&D Ireland
- Enrollment open: Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients (clinicaltrials.gov) - Feb 4, 2014
P=N/A, N=230, Recruiting, Sponsor: Valme University Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| samatasvir (IDX719) / Merck (MSD)
Enrollment closed: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - Jan 15, 2014
P2, N=143, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Olysio (simeprevir) / J&J, Medivir
Enrollment open: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation (clinicaltrials.gov) - Jan 8, 2014
P2, N=40, Recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Olysio (simeprevir) / J&J, Medivir
Enrollment change: A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection (clinicaltrials.gov) - Jan 1, 2014
P3, N=225, Recruiting, Sponsor: Janssen-Cilag International NV
Not yet recruiting --> Recruiting N=150 --> 225
- | GSK 2336805 / J&J, Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants. (clinicaltrials.gov) - Dec 19, 2013
P1, N=48, Active, not recruiting, Sponsor: Janssen R&D Ireland
- ||| samatasvir (IDX719) / Merck (MSD)
Enrollment change: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - Dec 3, 2013
P2, N=143, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
N=150 --> 225 N=90 --> 143
- ||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Enrollment change, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Dec 1, 2013
P2a, N=86, Recruiting, Sponsor: Janssen R&D Ireland
N=90 --> 143 N=46 --> 86
- ||||| Olysio (simeprevir) / J&J, Medivir
Enrollment change, Combination therapy: RESTORE: A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Na (clinicaltrials.gov) - Oct 21, 2013
P3, N=107, Completed, Sponsor: Janssen R&D Ireland
N=46 --> 86 N=85 --> 107
- |||||| Olysio (simeprevir) / J&J, Medivir
Enrollment open: A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection (clinicaltrials.gov) - Sep 23, 2013
P3, N=225, Recruiting, Sponsor: Janssen-Cilag International NV
N=85 --> 107 Not yet recruiting --> Recruiting
- | Olysio (simeprevir) / J&J, Medivir
New P2 trial: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation (clinicaltrials.gov) - Sep 8, 2013
P2, N=40, Recruiting, Sponsor: Janssen R&D Ireland
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 (clinicaltrials.gov) - Sep 8, 2013
P3, N=109, Completed, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- samatasvir (IDX719) / Merck (MSD)
Enrollment closed: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) (clinicaltrials.gov) - Aug 7, 2013
P1, N=32, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed: An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients (clinicaltrials.gov) - Aug 7, 2013
P3, N=458, Active, not recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | samatasvir (IDX719) / Merck (MSD)
New P1 trial: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) (clinicaltrials.gov) - Jul 23, 2013
P1, N=32, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
- | Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers (clinicaltrials.gov) - Jul 1, 2013
P1, N=12, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
- ||||| samatasvir (IDX719) / Merck (MSD)
New P2 trial: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - May 12, 2013
P2, N=143, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
- |||||||||| Olysio (simeprevir) / J&J, Medivir
New P3 trial: A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection (clinicaltrials.gov) - May 1, 2013
P3, N=225, Recruiting, Sponsor: Janssen-Cilag International NV
- samatasvir (IDX719) / Merck (MSD)
Enrollment closed: Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) (clinicaltrials.gov) - Mar 25, 2013
P1, N=40, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | samatasvir (IDX719) / Merck (MSD)
New P1 trial: Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) (clinicaltrials.gov) - Mar 17, 2013
P1, N=40, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
- | Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Pharmacokinetic Study to Assess the Effect of Food in Healthy Male Participants Receiving TMC435 (clinicaltrials.gov) - Feb 25, 2013
P1, N=24, Completed, Sponsor: Janssen Research & Development, LLC
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: QUEST-2: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants (clinicaltrials.gov) - Feb 25, 2013
P3, N=393, Completed, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: PROMISE: An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy (clinicaltrials.gov) - Feb 25, 2013
P3, N=394, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: QUEST-1: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients (clinicaltrials.gov) - Feb 20, 2013
P3, N=395, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Enrollment closed, Combination therapy: TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINF?-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINF?-2a and Ribavirin Therapy (clinicaltrials.gov) - Feb 13, 2013
P3, N=766, Active, not recruiting, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed: 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection (clinicaltrials.gov) - Dec 23, 2012
P2b, N=249, Active, not recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Olysio (simeprevir) / J&J, Medivir
Trial initiation date, Combination therapy: A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients (clinicaltrials.gov) - Dec 19, 2012
P2a, N=168, Completed, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Initiation date: Oct 2011 --> Jan 2012
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection (clinicaltrials.gov) - Dec 9, 2012
P3, N=79, Completed, Sponsor: Janssen Pharmaceutical K.K.
Initiation date: Oct 2011 --> Jan 2012 Active, not recruiting --> Completed
- Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients (clinicaltrials.gov) - Dec 6, 2012
P1, N=6, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Olysio (simeprevir) / J&J, Medivir
Enrollment change: TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin (clinicaltrials.gov) - Nov 28, 2012
P1, N=33, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed N=16 --> 33
- ||| Daklinza (daclatasvir) / BMS
Enrollment closed, Combination therapy: Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus (clinicaltrials.gov) - Nov 25, 2012
P2, N=180, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=16 --> 33 Not yet recruiting --> Active, not recruiting
- Olysio (simeprevir) / J&J, Medivir
Enrollment change: A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants (clinicaltrials.gov) - Nov 19, 2012
P1, N=36, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Active, not recruiting N=21 --> 36
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients (clinicaltrials.gov) - Nov 18, 2012
P3, N=183, Completed, Sponsor: Janssen Pharmaceutical K.K.
N=21 --> 36 Active, not recruiting --> Completed
- |||||||||| Olysio (simeprevir) / J&J, Medivir
New P3 trial: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 (clinicaltrials.gov) - Nov 13, 2012
P3, N=109, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
- |||||||||| Olysio (simeprevir) / J&J, Medivir
New P3 trial: An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients (clinicaltrials.gov) - Nov 12, 2012
P3, N=458, Active, not recruiting, Sponsor: Janssen R&D Ireland
- ||||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
New P2a trial, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Nov 7, 2012
P2a, N=86, Recruiting, Sponsor: Janssen R&D Ireland
- Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients (clinicaltrials.gov) - Oct 14, 2012
P1, N=6, Completed, Sponsor: Janssen R&D Ireland
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy (clinicaltrials.gov) - Oct 7, 2012
P3, N=106, Completed, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy (clinicaltrials.gov) - Sep 23, 2012
P3, N=49, Completed, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants (clinicaltrials.gov) - Sep 19, 2012
P1, N=36, Completed, Sponsor: Janssen Research & Development, LLC
- Olysio (simeprevir) / J&J, Medivir
Enrollment change: TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435 (clinicaltrials.gov) - Aug 15, 2012
P1, N=23, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed N=17 --> 23
- || Olysio (simeprevir) / J&J, Medivir
Enrollment change: A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435. (clinicaltrials.gov) - Jul 5, 2012
P1, N=72, Completed, Sponsor: Janssen R&D Ireland
N=17 --> 23 N=13 --> 72